[关键词]
[摘要]
近年来,肿瘤的免疫治疗已成为继传统手术、放疗、化疗、内分泌治疗和靶向药物治疗手段之后新的治疗方法,尤其以程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)位靶点的免疫检查点抑制治疗使得非小细胞肺癌、黑色素瘤等恶性实体肿瘤患者获得了有效持久的临床获益。PD-L1的检测是免疫检查点抑制剂治疗的关键环节,但在乳腺癌中的其检测方法和判定标准尚未统一。就PD-L1的检测方法以及其在乳腺癌各分子分型中的表达进行综述。
[Key word]
[Abstract]
In recent years, tumor immunotherapy has become a new anti-tumor therapy after surgery, radiotherapy, chemotherapy, endocrinotherapy, and targeted drug therapy. In particular, many of patients with non-small cell lung cancer, melanoma and other malignant solid tumors have gained effective and lasting clinical benefits from the immune-checkpoint inhibition therapy which targeting for PD-1/PD-L1. The detection of PD-L1 is a key link in the treatment of immune checkpoint inhibitors, but its detection methods and criteria in breast cancer have not been unified. This paper reviewed the detection methods of PD-L1 and its expression in subtypes of breast cancer.
[中图分类号]
R966
[基金项目]
国家自然科学基金资助项目(81903856)